DETROIT – More than half of chronic hepatitis C patients studied in a
new research project led by Henry Ford Hospital were not treated for
the potentially fatal disease, either because they couldn’t withstand
current therapies or because they, or their doctors, were waiting for
In a second, related study, Henry Ford researchers found that while
the disease is not yet curable, there is a significant “lost
opportunity” for hepatitis C patients to achieve the current best result
Both studies are being presented at the annual meeting of the
American Association for the Study of Liver Diseases being held in
Washington, DC, Nov. 1-5.
Stuart C. Gordon, M.D., director of the Hepatology section at Henry
Ford, and lead author of the first study, said it was launched because
of a lack of information about the subject.
“Limited data exist concerning the clinical disposition of U.S.
patients with chronic hepatitis C infection, including the reasons for
lack of antiviral treatment,” Dr. Gordon says. “Our goal was to add to
The team collected electronic health records from four large American
health systems of patients with confirmed chronic hepatitis C, a viral
infection that progressively scars the liver and eventually destroys the
organ and its vital functions.
Of these 4,271 patients diagnosed with the infection and still alive
through the end of 2011, the median age was 57; 57 percent were male; 29
percent were black and 97 percent were insured.
Included in the study data were the patients’ histories of antiviral treatments. The researchers found:
543, or 12.7 percent, had previously achieved a sustained virologic
response (SVR), meaning the hepatitis C virus was suppressed to the
point that it could no longer be detected in their blood for six months
after anti-viral treatment.
• 110, or 2.6 percent, were currently on anti-viral therapy.
Of the remaining 3,618 patients, 12 percent had never been followed up
within the health care system, despite clinical confirmation that they
had chronic hepatitis C.
• The majority, 55 percent, were not being
treated, either because of “absolute contraindications” to current
therapy – meaning the risk of available treatment is too high – or
because either the patient or physician were waiting for newer
• Another 12 percent of patients had chosen not to start treatment, despite a doctor’s recommendation to do so.
“These results confirm that only a small proportion of chronic
hepatitis C patients in American health care systems who were still
being followed at the end of 2011 had achieved an SVR with available
antiviral regimens,” Dr. Gordon said.
The second study sought to identify “lost opportunities” to treat
hepatitis C patients and achieve SVR, now the closest thing to a “cure”
for the disease.
“We looked at data regarding testing for chronic Hep C, patient
referral, patient visits and the start of treatment,” explains Kimberly
Ann Brown, M.D., division head of Gastroenterology at Henry Ford
Hospital and lead author of the study’s findings.
“In addition,” Dr. Brown says, “we considered patient age, race,
gender, income, marital status, psychiatric diagnoses and the number of
comorbidities, or co-existing diseases.”
The findings showed that of the 458 patients identified with a
positive hepatitis C antibody, only 117 received confirmatory testing,
were referred to a specialist and presented to the office for a visit.
Of the 117 patients who came for the specialty visit, only 21, or 17.9
percent, were felt to be appropriate treatment candidates.
“This data speaks to the significant “lost opportunity” we have, not
only in identifying patients with hepatitis C in our community, but also
in providing them with appropriate treatment options,” says Dr. Brown.
Press Release Source: http://www.henryford.com/body.cfm?id=46335&action=detail&ref=1995
Share This Page